The amplification of either mutant or wild-type alleles may impair the effectiveness of treatment by surpassing its inhibition capacity, as seen with EGFR amplification after EGFR-TKIs in NSCLC [27,168]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.